Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235862 | 0.84 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL2719765 | 0.83 | CRBN (0.54) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL2990979 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL24211424 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL1344880 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL21919776 | 0.79 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL21919210 | 0.79 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL23351432 | 0.79 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL20850213 | 0.77 | CRBN (0.47) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL22666465 | 0.77 | CRBN (0.47) | CRBNDDB1PKMPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | CRBN 2005/4885DDB1 3188/4885PKM 3807/4885 |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CRBN 407/4885DDB1 271/4885PKM 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.